Ecnoglutide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Ecnoglutide?
A biased GLP-1 receptor agonist from Sciwind Biosciences.
Phase 3 SLIMMER reported positive results in Lancet Diabetes Endocrinology 2025, and China approved the injection in 2026, for type 2 diabetes in January and weight management in March. It is not FDA-approved. Verdiva Bio registered two US phase 2 studies of an oral form: one finished in July 2026, and one was terminated as a business decision. The name also turns up on gray-market listings.
GLP-1 pipeline: survodutide, MariTide, ecnoglutide →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Ecnoglutide comes up on this site
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers